Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Cartesian Therapeutics, Inc. on June 13, 2025. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
A total of 21,868,804 shares were present or represented by proxy, representing approximately 84.31% of outstanding common stock. All three proposals were approved:
- Proposal 1 (Director Election): Three Class III Directors were elected to serve until the 2028 Annual Meeting.
- Timothy C. Barabe, M.B.A.: 19,208,637 votes FOR.
- Carsten Brunn, Ph.D.: 19,841,557 votes FOR.
- Nishan de Silva, M.D., M.B.A.: 19,840,306 votes FOR.
- Proposal 2 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers with 19,701,123 votes FOR.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025, with 21,830,780 votes FOR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class III Directors (serving until 2028).
- Confirm the engagement of Ernst & Young LLP for the fiscal year ending December 31, 2025.
- Review the Proxy Statement for detailed breakdowns of executive compensation approved in Proposal 2.
- Note that 2,008,823 broker non-votes were recorded for the director election and executive compensation proposals.